piracetam

Summary

Summary: A compound suggested to be both a nootropic and a neuroprotective agent.

Top Publications

  1. Ahishali B, Kaya M, Orhan N, Arican N, Ekizoglu O, Elmas I, et al. Effects of levetiracetam on blood-brain barrier disturbances following hyperthermia-induced seizures in rats with cortical dysplasia. Life Sci. 2010;87:609-19 pubmed publisher
    ..We investigated the effects of levetiracetam (LEV) on BBB integrity and the survival during hyperthermic seizures in rats with CD...
  2. Arayne M, Sultana N, Siddiqui F, Mirza A, Qureshi F, Zuberi M. Simultaneous determination of piracetam and its four impurities by RP-HPLC with UV detection. J Chromatogr Sci. 2010;48:589-94 pubmed
    A simple and rapid high-performance liquid chromatographic method for the separation and determination of piracetam and its four impurities, 2-oxopyrrolidin-1-yl)acetic acid, pyrrolidin-2-one, methyl (2-oxopyrrolidin-1-yl)acetate, and ..
  3. Talos D, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkerth R, et al. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr Res. 2013;73:24-30 pubmed publisher
    ..Preclinical data regarding the acute or long-term efficacy of LEV are lacking...
  4. Muley M, Thakare V, Patil R, Kshirsagar A, Naik S. Silymarin improves the behavioural, biochemical and histoarchitecture alterations in focal ischemic rats: a comparative evaluation with piracetam and protocatachuic acid. Pharmacol Biochem Behav. 2012;102:286-93 pubmed publisher
    Comparative neuroprotective potential of silymarin, piracetam and protocatechuic acid ethyl ester (PCA) was evaluated in focal ischemic rats...
  5. Belcastro V, Pierguidi L, Tambasco N. Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. Brain Dev. 2011;33:289-93 pubmed publisher
    ..In this review, the potential neuroprotective role in brain ischemia and the therapeutic implications of levetiracetam in post-stroke epilepsy are discussed...
  6. Kurz C, Ungerer I, Lipka U, Kirr S, Schütt T, Eckert A, et al. The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide. Br J Pharmacol. 2010;160:246-57 pubmed publisher
    ..The metabolic enhancer piracetam has been shown to improve mitochondrial dysfunction following brain aging and experimentally induced oxidative ..
  7. Cotton B, Kao L, Kozar R, Holcomb J. Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis. J Trauma. 2011;71:375-9 pubmed publisher
    ..The purpose of this study was to evaluate whether phenytoin or levetiracetam would be more cost-effective in preventing early post-TBI seizures and reducing their negative impact on TBI outcomes...
  8. Crepeau A, Treiman D. Levetiracetam: a comprehensive review. Expert Rev Neurother. 2010;10:159-71 pubmed publisher
    ..We also discuss the direction antiepileptic drug development will take in the future...
  9. Stienen M, Haghikia A, Dambach H, Thone J, Wiemann M, Gold R, et al. Anti-inflammatory effects of the anticonvulsant drug levetiracetam on electrophysiological properties of astroglia are mediated via TGF?1 regulation. Br J Pharmacol. 2011;162:491-507 pubmed publisher
    ..Evidence so far suggests a mode of action different from that of classical AEDs. We have shown that LEV restored functional gap junction coupling and basic membrane properties in an astrocytic inflammatory model in vitro...

More Information

Publications62

  1. Weigt S, Huebler N, Strecker R, Braunbeck T, Broschard T. Zebrafish (Danio rerio) embryos as a model for testing proteratogens. Toxicology. 2011;281:25-36 pubmed publisher
    ..Along with other findings, our results indicate that zebrafish embryos are a useful alternative method for traditional teratogenicity testing with mammalian species...
  2. Russo E, Citraro R, Scicchitano F, De Fazio S, Perrotta I, Perrota I, et al. Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model. Epilepsia. 2011;52:1341-50 pubmed publisher
    ..Here, we examined the effects of long-term treatment with several AEDs on absence seizure development and onset of depressive-like behavior in WAG/Rij rats at different ages, using a forced swimming test (FST)...
  3. Yan H, Ishihara K, Seki T, Hanaya R, Kurisu K, Arita K, et al. Inhibitory effects of levetiracetam on the high-voltage-activated L-type Ca²? channels in hippocampal CA3 neurons of spontaneously epileptic rat (SER). Brain Res Bull. 2013;90:142-8 pubmed publisher
  4. Meehan A, Yang X, McAdams B, Yuan L, Rothman S. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J Neurophysiol. 2011;106:1227-39 pubmed publisher
    ..Our results identify a unique neurobiological explanation for LEV's highly selective antiepileptic effect and suggest that synaptic vesicle proteins might be appropriate targets for the development of other neuroactive drugs...
  5. Meehan A, Yang X, Yuan L, Rothman S. Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia. 2012;53:469-76 pubmed publisher
    ..Because there are differences in excitatory and inhibitory transmitter release mechanisms, and there are suggestions that neurons differ in their SV2A expression, we were curious whether LEV also reduces inhibitory transmission...
  6. Fukuyama K, Tanahashi S, Nakagawa M, Yamamura S, Motomura E, Shiroyama T, et al. Levetiracetam inhibits neurotransmitter release associated with CICR. Neurosci Lett. 2012;518:69-74 pubmed publisher
  7. Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol. 2011;44:265-9 pubmed publisher
    ..Intravenous levetiracetam can be used as monotherapy and adjunctively in acute seizure management during the neonatal period...
  8. Shallcross R, Bromley R, Irwin B, Bonnett L, Morrow J, Baker G. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011;76:383-9 pubmed publisher
  9. Abend N, Gutierrez Colina A, Monk H, Dlugos D, Clancy R. Levetiracetam for treatment of neonatal seizures. J Child Neurol. 2011;26:465-70 pubmed publisher
    ..Further study is warranted to determine optimal levetiracetam dosing in neonates and to compare efficacy with other antiseizure medications...
  10. Kilicdag H, Daglioglu K, Erdogan S, Guzel A, Sencar L, Polat S, et al. The effect of levetiracetam on neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Early Hum Dev. 2013;89:355-60 pubmed publisher
    ..Potential effects of LEV on neuronal apoptosis in HIBI have not previously been reported in literature...
  11. Costa R, Fernandes M, de Souza Pinto N, Vercesi A. Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. Eur J Pharmacol. 2013;701:82-6 pubmed publisher
    ..prostate cancer cell death as well as the mechanisms of cell death protection by l-carnitine or piracetam. These compounds are known to prevent and/or protect against cell death mediated by oxidative mitochondrial ..
  12. Malykh A, Sadaie M. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287-312 pubmed publisher
    ..Since the last meta-analysis of the clinical efficacy of piracetam, more information has accumulated...
  13. Dahlin M, Wide K, Ohman I. Age and comedications influence levetiracetam pharmacokinetics in children. Pediatr Neurol. 2010;43:231-5 pubmed publisher
    ..In conclusion, younger age and comedication with an enzyme inducer increased levetiracetam clearance. This finding should be taken into account when treating individual patients...
  14. Muley M, Thakare V, Patil R, Bafna P, Naik S. Amelioration of cognitive, motor and endogenous defense functions with silymarin, piracetam and protocatechuic acid in the cerebral global ischemic rat model. Life Sci. 2013;93:51-7 pubmed publisher
    The neuroprotective activities of silymarin, piracetam and protocatechuic acid ethyl ester (PCA) on cerebral global ischemic/reperfusion were evaluated in a rat model.
  15. Taylor S, Heinrichs R, Janzen J, Ehtisham A. Levetiracetam is associated with improved cognitive outcome for patients with intracranial hemorrhage. Neurocrit Care. 2011;15:80-4 pubmed publisher
    ..Levetiracetam is known to cause less cognitive disruption and may be a suitable alternative for seizure prophylaxis. Cognitive outcomes in ICH patients receiving seizure prophylaxis with levetiracetam or phenytoin are compared...
  16. Ramantani G, Ikonomidou C, Walter B, Rating D, Dinger J. Levetiracetam: safety and efficacy in neonatal seizures. Eur J Paediatr Neurol. 2011;15:1-7 pubmed publisher
    ..Levetiracetam (LEV) may have a more favorable profile since it does not cause neuronal apoptosis in infant rodents...
  17. Aiguabella M, Falip M, Villanueva V, de la Pena P, Molins A, Garcia Morales I, et al. Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study. Seizure. 2011;20:60-4 pubmed publisher
    ..Intravenous levetiracetam (ivLEV) is a new antiepileptic drug with interesting properties for SE...
  18. Murphy Human T, Welch E, Zipfel G, Diringer M, Dhar R. Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage. World Neurosurg. 2011;75:269-74 pubmed publisher
    ..This study sought to compare the incidence of seizures before and after this change to evaluate whether a short course of levetiracetam would be as effective in preventing in-hospital seizures...
  19. Merhar S, SCHIBLER K, Sherwin C, Meinzen Derr J, Shi J, Balmakund T, et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr. 2011;159:152-154.e3 pubmed publisher
    ..Neonates were found to have lower clearance, higher volume of distribution, and a longer half-life as compared with older children and adults. Mild somnolence was the only adverse effect...
  20. Hadad G, Abdel Salam R, Emara S. Optimized and validated flow-injection spectrophotometric analysis of topiramate, piracetam and levetiracetam in pharmaceutical formulations. Acta Pharm. 2011;61:377-89 pubmed publisher
    Application of a sensitive and rapid flow injection analysis (FIA) method for determination of topiramate, piracetam, and levetiracetam in pharmaceutical formulations has been investigated...
  21. Price M. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain. 2004;20:33-6 pubmed
    ..A nerve conduction study demonstrated a severe bilateral sensorimotor peripheral neuropathy with axonal and demyelinating features. Treatment with 1000 mg levetiracetam bid resulted in complete absence of pain...
  22. Zheng Y, Moussally J, Cash S, Karnam H, Cole A. Intravenous levetiracetam in the rat pilocarpine-induced status epilepticus model: behavioral, physiological and histological studies. Neuropharmacology. 2010;58:793-8 pubmed publisher
    ..We sought to determine the effect of LEV administered intravenously in a chemoconvulsant model of status epilepticus...
  23. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007;13:57-78 pubmed
  24. Krief P, Li Kan -, Maytal J. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. J Child Neurol. 2008;23:582-4 pubmed publisher
    ..Adverse effects occurred in 2 patients and were behavioral in nature. Levetiracetam treatment was safe and effective in this group of very young patients with various types of epilepsy...
  25. Enggaard T, Klitgaard N, Sindrup S. Specific effect of levetiracetam in experimental human pain models. Eur J Pain. 2006;10:193-8 pubmed
    ..Levetiracetam is a new antiepileptic drug. There is only limited experience with levetiracetam in clinical neuropathic pain...
  26. Newton H, Goldlust S, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol. 2006;78:99-102 pubmed
    ..LEV was very effective and well tolerated in brain tumor patients with seizures, and should be considered for add-on therapy to current AEDs, or as a substitute anti-convulsant for monotherapy...
  27. Wang H, Gao J, Lassiter T, McDonagh D, Sheng H, Warner D, et al. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care. 2006;5:71-8 pubmed
    ..In the current study, we test the hypothesis that levetiracetam, an anticonvulsant with favorable interaction and adverse event profiles, is neuroprotective in clinically relevant models of SAH and closed head injury (CHI)...
  28. Szalma I, Kiss A, Kardos L, Horváth G, Nyitrai E, Tordai Z, et al. Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. Ann Thorac Surg. 2006;82:1430-5 pubmed
    ..No effective treatment is currently available. The aim of this study was to evaluate the effectiveness of piracetam to treat the cognitive impairment after CABG in an investigator-initiated, double-blind, placebo-controlled, ..
  29. Yang X, Weisenfeld A, Rothman S. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia. 2007;48:1861-9 pubmed
    ..Using a combination of electrophysiological and cellular imaging techniques, we carefully tested the hypothesis that LEV directly interferes with neurotransmitter release...
  30. Fay M, Sheth R, Gidal B. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. Clin Ther. 2005;27:594-8 pubmed
    ..Although previous studies have suggested that administration with food does not affect the overall absorption of LEV, there is a lack of data regarding concomitant administration with ENFs...
  31. Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia. 2009;50:1150-7 pubmed publisher
    ..To develop a population pharmacokinetic model to evaluate the demographic and physiologic determinants of levetiracetam (LEV) pharmacokinetics (PK) and to suggest recommended doses of LEV in children...
  32. Gurses C, Ekizoglu O, Orhan N, Ustek D, Arican N, Ahishali B, et al. Levetiracetam decreases the seizure activity and blood-brain barrier permeability in pentylenetetrazole-kindled rats with cortical dysplasia. Brain Res. 2009;1281:71-83 pubmed publisher
    ..The present study showed that LEV decreased the increased BBB permeability considerably by diminishing vesicular transport in epileptic seizures induced by convulsive PTZ challenge in kindled animals with CD...
  33. Nagarkatti N, Deshpande L, Delorenzo R. Levetiracetam inhibits both ryanodine and IP3 receptor activated calcium induced calcium release in hippocampal neurons in culture. Neurosci Lett. 2008;436:289-93 pubmed publisher
    ..Thus, the ability of LEV to modulate the two major CICR systems demonstrates an important molecular effect of this agent on a major second messenger system in neurons...
  34. Vinogradova L, Van Rijn C. Anticonvulsive and antiepileptogenic effects of levetiracetam in the audiogenic kindling model. Epilepsia. 2008;49:1160-8 pubmed publisher
    ..To study anticonvulsive and antiepileptogenic effects of singe levetiracetam (LEV) administration in the model of audiogenic kindling...
  35. Woods S, Saksa J, Baker C, Cohen S, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69:546-54 pubmed
    ..The goal of this study was to evaluate the efficacy and safety of levetiracetam versus placebo for tardive dyskinesia (TD)...
  36. Contin M, Albani F, Riva R, Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2004;26:375-9 pubmed
    ..Concomitant AED inducers can contribute to variability in levetiracetam disposition in patients with epilepsy. The observed differences were moderate and possibly of minor clinical significance...
  37. Milligan T, Hurwitz S, Bromfield E. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008;71:665-9 pubmed publisher
    ..This retrospective study compared the use of LEV and PHT as monotherapy prophylaxis following supratentorial neurosurgery...
  38. Glauser T, Mitchell W, Weinstock A, Bebin M, Chen D, Coupez R, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia. 2007;48:1117-22 pubmed
    ..To assess the single-dose pharmacokinetics of levetiracetam and its major metabolite ucb L057 in infants and young children with epilepsy...
  39. Newton H, Dalton J, Goldlust S, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol. 2007;84:293-6 pubmed
    ..LEV was very effective and well tolerated in MBT patients with seizures and should be considered for add-on therapy or as a substitute AED for monotherapy...
  40. Patsalos P, Ghattaura S, Ratnaraj N, Sander J. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia. 2006;47:1818-21 pubmed
  41. Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Muller W. Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol. 2006;147:199-208 pubmed
    ..2.--Since the cognition-improving effects of the standard nootropic piracetam are usually more pronounced under such pathological conditions and young healthy animals usually benefit little ..
  42. Kinrys G, Wygant L, Pardo T, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006;67:211-4 pubmed
    ..To assess the use of levetiracetam, a novel anticonvulsant agent, in the treatment of refractory posttraumatic stress disorder (PTSD)...
  43. Cataldi M, Lariccia V, Secondo A, di Renzo G, Annunziato L. The antiepileptic drug levetiracetam decreases the inositol 1,4,5-trisphosphate-dependent [Ca2+]I increase induced by ATP and bradykinin in PC12 cells. J Pharmacol Exp Ther. 2005;313:720-30 pubmed
    ..Because of the relevant implications of IP(3)-dependent Ca(2+) release in neuron excitability and epileptogenesis, this novel effect of LEV could provide a useful insight into the mechanisms underlying its antiepileptic properties...
  44. Krauss G, Betts T, Abou Khalil B, Gergey G, Yarrow H, Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure. 2003;12:617-20 pubmed
    ..This is preliminary evidence that LEV is effective for treating idiopathic generalised epilepsy...
  45. Patsalos P. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707-24 pubmed
    ..Overall, the pharmacokinetic characteristics of levetiracetam are highly favourable and make its clinical use simple and straightforward...
  46. Szaflarski J, Sangha K, Lindsell C, Shutter L. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010;12:165-72 pubmed publisher
    ..LEV appears to be an alternative to PHT for seizure prophylaxis in this setting. ..
  47. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu Z, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47:1128-35 pubmed
    ..The secondary objective was to assess LEV pharmacokinetics...
  48. Szaflarski J, Meckler J, Szaflarski M, Shutter L, Privitera M, Yates S. Levetiracetam use in critically ill patients. Neurocrit Care. 2007;7:140-7 pubmed
    ..Levetiracetam (LEV) is used in the setting of acute brain injury for seizure treatment or prophylaxis but its safety and efficacy in this setting is unknown...
  49. Wheble P, Sena E, Macleod M. A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. Cerebrovasc Dis. 2008;25:5-11 pubmed
    b>Piracetam was a candidate neuroprotective drug for acute stroke ineffective in clinical trial...
  50. Toublanc N, Sargentini Maier M, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin Pharmacokinet. 2008;47:333-41 pubmed
    ..To characterize levetiracetam pharmacokinetics, identify significant covariate relationships and identify doses in children that achieve blood concentrations similar to those observed in adults...
  51. Matveeva E, Vanaman T, Whiteheart S, Slevin J. Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes. Epilepsia. 2008;49:1749-58 pubmed publisher
    ..The present studies probe the persistence of 7SC accumulation and the effect of the anticonvulsant, levetiracetam (LEV), on 7SC and SNARE regulators...
  52. Silverstein F, Ferriero D. Off-label use of antiepileptic drugs for the treatment of neonatal seizures. Pediatr Neurol. 2008;39:77-9 pubmed publisher
    ..These results highlight the urgent need for rigorous clinical trials to understand the risks and benefits of new drug therapies for neonatal seizures...
  53. Li S, Cao J, Xiao N, Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol. 2010;25:609-13 pubmed publisher
    ..5% of patients, all adverse effects were tolerable or resolved with time or discontinuation. Therefore, the authors conclude that levetiracetam treatment is effective and safe in young children with refractory epilepsy...